Voyager Therapeutics (VYGR) Upgraded to Strong-Buy by BidaskClub

Voyager Therapeutics (NASDAQ:VYGR) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Friday.

Several other equities research analysts have also weighed in on the stock. Canaccord Genuity reiterated a “buy” rating and set a $26.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday. ValuEngine upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. Zacks Investment Research lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. Chardan Capital reiterated a “hold” rating and set a $17.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Finally, Wedbush reiterated a “positive” rating and set a $31.00 price objective (down previously from $36.00) on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $26.90.

Shares of Voyager Therapeutics (NASDAQ:VYGR) traded up $0.15 during mid-day trading on Friday, hitting $21.85. 139,112 shares of the stock traded hands, compared to its average volume of 363,330. Voyager Therapeutics has a twelve month low of $8.10 and a twelve month high of $25.99. The company has a market capitalization of $592.92 and a PE ratio of -7.69.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.17). Voyager Therapeutics had a negative return on equity of 65.50% and a negative net margin of 1,195.63%. analysts forecast that Voyager Therapeutics will post -2.99 earnings per share for the current year.

In related news, insider Bernard Ravina sold 5,490 shares of the stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $13.63, for a total transaction of $74,828.70. Following the sale, the insider now owns 10,983 shares in the company, valued at $149,698.29. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last quarter, insiders have sold 14,610 shares of company stock worth $207,158. 8.00% of the stock is owned by company insiders.

Several large investors have recently made changes to their positions in the business. Schwab Charles Investment Management Inc. increased its stake in shares of Voyager Therapeutics by 0.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 29,035 shares of the company’s stock valued at $261,000 after purchasing an additional 114 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Voyager Therapeutics by 8.9% in the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after purchasing an additional 1,399 shares during the period. California State Teachers Retirement System increased its stake in shares of Voyager Therapeutics by 8.4% in the second quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock valued at $231,000 after purchasing an additional 2,000 shares during the period. TIAA CREF Investment Management LLC increased its stake in shares of Voyager Therapeutics by 11.8% in the second quarter. TIAA CREF Investment Management LLC now owns 37,295 shares of the company’s stock valued at $334,000 after purchasing an additional 3,939 shares during the period. Finally, Rhumbline Advisers increased its stake in shares of Voyager Therapeutics by 34.7% in the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after purchasing an additional 4,144 shares during the period. Institutional investors own 36.01% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/27/voyager-therapeutics-vygr-upgraded-to-strong-buy-by-bidaskclub.html.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply